Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies
An intriguing aspect of restrictive cardiomyopathies (RCM) is the microbiome role in the natural history of the disease. These cardiomyopathies are often difficult to diagnose and so result in significant morbidity and mortality. The human microbiome, composed of billions of microorganisms, influenc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/144 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588976084484096 |
|---|---|
| author | Samuel Jaimez-Alvarado Itzel Ivonn López-Tenorio Javier Barragán-De los Santos Dannya Coral Bello-Vega Francisco Javier Roldán Gómez Amedeo Amedei Enrique Alexander Berrios-Bárcenas María Magdalena Aguirre-García |
| author_facet | Samuel Jaimez-Alvarado Itzel Ivonn López-Tenorio Javier Barragán-De los Santos Dannya Coral Bello-Vega Francisco Javier Roldán Gómez Amedeo Amedei Enrique Alexander Berrios-Bárcenas María Magdalena Aguirre-García |
| author_sort | Samuel Jaimez-Alvarado |
| collection | DOAJ |
| description | An intriguing aspect of restrictive cardiomyopathies (RCM) is the microbiome role in the natural history of the disease. These cardiomyopathies are often difficult to diagnose and so result in significant morbidity and mortality. The human microbiome, composed of billions of microorganisms, influences various physiological and pathological processes, including cardiovascular health. Studies have shown that gut dysbiosis, an imbalance in the composition of intestinal bacteria, can contribute to systemic inflammation, a key factor in many cardiovascular conditions. An increase in gut permeability, frequently caused by dysbiosis, allows bacterial endotoxins to enter the bloodstream, activating inflammatory pathways that exacerbate cardiac dysfunction. Recent reports highlight the potential role of microbiome in amyloidogenesis, as certain bacteria produce proteins that accelerate the formation of amyloid fibrils. Concurrently, advancements in amyloidosis treatments have sparked renewed hopes, marking a promising era for managing these kinds of diseases. These findings suggest that the gut–heart axis may be a potential factor in the development and progression of cardiovascular disease like RCM, opening new paths for therapeutic intervention. The aim of this review is to provide a detailed overview of the gut–heart axis, focusing on RCM. |
| format | Article |
| id | doaj-art-6746aafdfdc8410b9c84fdbdf24550c6 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-6746aafdfdc8410b9c84fdbdf24550c62025-01-24T13:24:10ZengMDPI AGBiomedicines2227-90592025-01-0113114410.3390/biomedicines13010144Gut-Heart Axis: Microbiome Involvement in Restrictive CardiomyopathiesSamuel Jaimez-Alvarado0Itzel Ivonn López-Tenorio1Javier Barragán-De los Santos2Dannya Coral Bello-Vega3Francisco Javier Roldán Gómez4Amedeo Amedei5Enrique Alexander Berrios-Bárcenas6María Magdalena Aguirre-García7Unidad de Investigación UNAM-INC, División de Investigación, Facultad de Medicina, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoUnidad de Investigación UNAM-INC, División de Investigación, Facultad de Medicina, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoUnidad de Investigación UNAM-INC, División de Investigación, Facultad de Medicina, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoUnidad de Investigación UNAM-INC, División de Investigación, Facultad de Medicina, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoOutpatient Care Department, Cardiomyopathy Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, MexicoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, ItalyOutpatient Care Department, Cardiomyopathy Clinic, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, MexicoUnidad de Investigación UNAM-INC, División de Investigación, Facultad de Medicina, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City 14080, MexicoAn intriguing aspect of restrictive cardiomyopathies (RCM) is the microbiome role in the natural history of the disease. These cardiomyopathies are often difficult to diagnose and so result in significant morbidity and mortality. The human microbiome, composed of billions of microorganisms, influences various physiological and pathological processes, including cardiovascular health. Studies have shown that gut dysbiosis, an imbalance in the composition of intestinal bacteria, can contribute to systemic inflammation, a key factor in many cardiovascular conditions. An increase in gut permeability, frequently caused by dysbiosis, allows bacterial endotoxins to enter the bloodstream, activating inflammatory pathways that exacerbate cardiac dysfunction. Recent reports highlight the potential role of microbiome in amyloidogenesis, as certain bacteria produce proteins that accelerate the formation of amyloid fibrils. Concurrently, advancements in amyloidosis treatments have sparked renewed hopes, marking a promising era for managing these kinds of diseases. These findings suggest that the gut–heart axis may be a potential factor in the development and progression of cardiovascular disease like RCM, opening new paths for therapeutic intervention. The aim of this review is to provide a detailed overview of the gut–heart axis, focusing on RCM.https://www.mdpi.com/2227-9059/13/1/144amyloidosisFabry’s diseaseWilson’s diseasecardiac systemic sclerosissarcoidosisPompe’s disease |
| spellingShingle | Samuel Jaimez-Alvarado Itzel Ivonn López-Tenorio Javier Barragán-De los Santos Dannya Coral Bello-Vega Francisco Javier Roldán Gómez Amedeo Amedei Enrique Alexander Berrios-Bárcenas María Magdalena Aguirre-García Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies Biomedicines amyloidosis Fabry’s disease Wilson’s disease cardiac systemic sclerosis sarcoidosis Pompe’s disease |
| title | Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies |
| title_full | Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies |
| title_fullStr | Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies |
| title_full_unstemmed | Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies |
| title_short | Gut-Heart Axis: Microbiome Involvement in Restrictive Cardiomyopathies |
| title_sort | gut heart axis microbiome involvement in restrictive cardiomyopathies |
| topic | amyloidosis Fabry’s disease Wilson’s disease cardiac systemic sclerosis sarcoidosis Pompe’s disease |
| url | https://www.mdpi.com/2227-9059/13/1/144 |
| work_keys_str_mv | AT samueljaimezalvarado gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT itzelivonnlopeztenorio gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT javierbarragandelossantos gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT dannyacoralbellovega gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT franciscojavierroldangomez gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT amedeoamedei gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT enriquealexanderberriosbarcenas gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies AT mariamagdalenaaguirregarcia gutheartaxismicrobiomeinvolvementinrestrictivecardiomyopathies |